NCT05126966 (Diagrid) is a Phase 3 clinical trial of Ranibizumab in Neovascular Age-Related Macular Degeneration, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT05126966?

NCT05126966 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT05126966?

Interventions in NCT05126966: Ranibizumab, Aflibercept, Port Delivery System with ranibizumab (PDS).

What condition does NCT05126966 study?

NCT05126966 studies Neovascular Age-Related Macular Degeneration.

Is NCT05126966 still recruiting?

NCT05126966 is currently withdrawn. Last updated 18 January 2024.

Last reviewed 2024-01-18 · How we verify

NCT05126966: Diagrid

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration

Withdrawn Phase 3 Last updated 18 January 2024

What this trial tests

Phase 3 trial testing Ranibizumab in Neovascular Age-Related Macular Degeneration. Withdrawn.

Timeline

29 December 2023

Primary endpoint
31 January 2025

30 January 2026

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Start date	29 December 2023
Primary completion	31 January 2025
Estimated completion	30 January 2026
Sites	10 locations across Denmark, Hong Kong, Greece, Argentina, Thailand, Portugal, Spain

Drugs / interventions tested

Ranibizumab — full drug profile →
Aflibercept (AFLIBERCEPT) — full drug profile →
Port Delivery System with ranibizumab (PDS)

Conditions studied

Neovascular Age-Related Macular Degeneration — all drugs for Neovascular Age-Related Macular Degeneration →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

50 and older, any sex, with Neovascular Age-Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the effectiveness and safety of a 36-week refill regimen for the Port Delivery System with ranibizumab 100 mg/mL (PDS Q36W) compared with intravitreal injections of aflibercept (2 mg) administered per treat-and-extend (aflibercept T\&E) in subjects with neovascular (wet) age-related macular degeneration (nAMD).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Alternative Routes of Administration for Therapeutic Antibodies-State of the Art.
Pitiot A, Heuzé-Vourc'h N, Sécher T. · · 2022 · cited 45× · PMID 36134952 · DOI 10.3390/antib11030056
High-efficiency base editing in the retina in primates and human tissues.
Muller A, Sullivan J, Schwarzer W, Wang M, et al · · 2025 · cited 34× · PMID 39779923 · DOI 10.1038/s41591-024-03422-8
Developing and validating a multivariable prediction model which predicts progression of intermediate to late age-related macular degeneration-the PINNACLE trial protocol.
Sutton J, Menten MJ, Riedl S, Bogunović H, et al · · 2023 · cited 26× · PMID 35614343 · DOI 10.1038/s41433-022-02097-0
TBC1D32 variants disrupt retinal ciliogenesis and cause retinitis pigmentosa.
Bocquet B, Borday C, Erkilic N, Mamaeva D, et al · · 2023 · cited 14× · PMID 37768732 · DOI 10.1172/jci.insight.169426
An Update on Strategies to Deliver Protein and Peptide Drugs to the Eye.
Boddu SHS, Acharya D, Hala V, Jani H, et al · · 2023 · cited 12× · PMID 37810716 · DOI 10.1021/acsomega.3c02897
Clinical Trials and Future Outlooks of the Port Delivery System with Ranibizumab: A Narrative Review.
Lowater SJ, Grauslund J, Subhi Y, Vergmann AS. · · 2024 · cited 10× · PMID 38055121 · DOI 10.1007/s40123-023-00843-5
Establishing Fully-Automated Fundus-Controlled Dark Adaptometry: A Validation and Retest-Reliability Study.
Oertli JM, Pfau K, Scholl HPN, Jeffrey BG, et al · · 2023 · cited 9× · PMID 38112496 · DOI 10.1167/tvst.12.12.18
Deep Learning-Based Clustering of OCT Images for Biomarker Discovery in Age-Related Macular Degeneration (PINNACLE Study Report 4).
Holland R, Kaye R, Hagag AM, Leingang O, et al · · 2024 · cited 8× · PMID 39139544 · DOI 10.1016/j.xops.2024.100543

Verify or expand the search:

Other trials of Ranibizumab

Trials testing the same drug.

NCT06847542 — A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD · Phase 3 · recruiting
NCT06957080 — A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME · Phase 2, PHASE3 · active not recruiting
NCT06176352 — A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Path · Phase 3 · active not recruiting
NCT05480293 — This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab · Phase 3 · unknown
NCT05576792 — A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in · completed

Other recruiting trials for Neovascular Age-Related Macular Degeneration

Currently open trials in the same condition.

NCT06491914 — A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related · Phase 3 · active not recruiting
NCT06223958 — Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects Wi · Phase 3 · active not recruiting
NCT03683251 — Extension Study for the Port Delivery System With Ranibizumab (Portal) · Phase 3 · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05126966 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 18 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05126966.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing